Medifast (NYSE:MED), which primarily engages in the production, distribution, and sale of weight loss products, has set an optimistic revenue target of $1 billion by 2017 from FY12 revenue of $357 million. Achievement of the target growth would imply revenue CAGR of 23% over the next five years. This investment note discusses the possibility of achieving this target considering the company's growth strategy and its implications for the company's stock. Based on the arguments presented below, I am of the opinion that the company will disappoint on the growth front and the stock will be a victim of over optimism.
Talking about over optimism, Weight Watchers International (NYSE:WTW), another company that provides weight management services, slumped...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|
|PRO Top long ideas returned 21.7% in 2016**|